The effect of laparoscopic sleeve gastrectomy on morbid obesity and obesity-related comorbidities: A cohort study

08.04.2016 10:53
Ulus Cerrahi Derg. 2015; 31(4): 202–206.
Published online 2015 Apr 9. doi:  10.5152/UCD.2015.2993
PMCID: PMC4674040

The effect of laparoscopic sleeve gastrectomy on morbid obesity and obesity-related comorbidities: A cohort study

Abstract

Objective:

Bariatric surgery with multidisciplinary management is a more effective method to treat morbid obesity and obesity-related comorbidities compared with nonsurgical treatments. Laparoscopic sleeve gastrectomy (LSG) was initially performed as the first stage of biliopancreatic diversion with duodenal switch in the super-obese population. In the past few years, however, LSG has been performed as a definitive procedure because of its promising early and midterm results. The aim of this study is to evaluate the efficacy of our initial LSG series of 73 patients on excess weight loss (EWL) and resolution of obesity-related comorbidities in short-term follow-up.

Material and Methods:

From March 2013 to May 2014, 78 morbid obese patients with an average body mass index (BMI) of 46.3 kg/m2 underwent LSG. There is a 9-month follow-up period on average. Five patients were excluded from the study, because they could not be contacted. Comorbidities, preintervention BMI, glucose, HbA1c, and lipid profiles were recorded at 1, 6, and 12 months postintervention.

Results:

After the surgery, the percent EWL was 58%. The mean serum glucose level, HbA1c level, LDL-cholesterol level, triglyceride level, insulin, and insulin resistance decreased significantly and the mean HDL-cholesterol level increased.

Conclusion:

For the resolution of comorbidities, LSG may be used as an effective bariatric and metabolic surgery.

Keywords: Sleeve gastrectomy, bariatric surgery, morbid obesity

Geri